Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-0390 in Gliomas
NCT06636162Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DSP-0390 in glioma (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Unbound DSP-0390 concentration in non-enhancing tumor tissue at 2 weeks and Changes in DSP-0390 concentration in plasma at 2 weeks. Started Apr 2025; status: recruiting.
02
Drugs
DSP-0390
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06636162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636162.